{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:26:40Z","timestamp":1779229600421,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research Fund of University Hospital Plzen","award":["FN 00669806"],"award-info":[{"award-number":["FN 00669806"]}]},{"name":"Charles University Research Fund","award":["Progres Q39"],"award-info":[{"award-number":["Progres Q39"]}]},{"name":"European Regional Development Fund-Project","award":["CZ.02.1.01\/0.0\/0.0\/17_048\/0007280"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/17_048\/0007280"]}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"crossref","award":["NV19-08-00250"],"award-info":[{"award-number":["NV19-08-00250"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union's Horizon 2020","award":["N\u00ba856620"],"award-info":[{"award-number":["N\u00ba856620"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11523-021-00829-y","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T10:03:02Z","timestamp":1628330582000},"page":"643-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-7385","authenticated-orcid":false,"given":"Ond\u0159ej","family":"Fiala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Osta\u0161ov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Rozsypalov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Hora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ond\u0159ej","family":"\u0160orejs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"\u0160ustr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbora","family":"Bendov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Tr\u00e1vn\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Filipovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jind\u0159ich","family":"F\u00ednek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"key":"829_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11:79\u201387.","journal-title":"World J Oncol."},{"key":"829_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","volume":"20","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Autorino R, Bruni G, Carten\u00ec G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20:1535\u201342.","journal-title":"Ann Oncol"},{"key":"829_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763\u201373.","journal-title":"J Natl Cancer Inst"},{"key":"829_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000338175","volume":"35","author":"S Szmit","year":"2012","unstructured":"Szmit S, Zaborowska M, Wa\u015bko-Grabowska A, \u017bo\u0142nierek J, Nurzy\u0144ski P, Filipiak KJ, et al. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood Press Res. 2012;35:468\u201376.","journal-title":"Kidney Blood Press Res"},{"key":"829_CR5","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","volume":"19","author":"ML Telli","year":"2008","unstructured":"Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19:1613\u20138.","journal-title":"Ann Oncol"},{"key":"829_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/aje\/kwm321","volume":"167","author":"S Weikert","year":"2008","unstructured":"Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167:438\u201346.","journal-title":"Am J Epidemiol"},{"key":"829_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"OP Hamnvik","year":"2015","unstructured":"Hamnvik OP, Choueiri TK, Turchin A. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311\u20139.","journal-title":"Cancer"},{"key":"829_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","volume":"26","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol. 2015;26:1128\u201333.","journal-title":"Ann Oncol"},{"key":"829_CR9","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","volume":"47","author":"D Keizman","year":"2011","unstructured":"Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47:1955\u201361.","journal-title":"Eur J Cancer"},{"key":"829_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/JCO.2019.37.7_suppl.467","volume":"37","author":"VG Patel","year":"2019","unstructured":"Patel VG, Oh WK, Galsky MD, Liaw BCH, Tsao CK. Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC). J Clin Oncol. 2019;37:467\u2013467.","journal-title":"J Clin Oncol"},{"key":"829_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3747\/co.19.972","volume":"19","author":"P Larochelle","year":"2012","unstructured":"Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, et al. Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol. 2012;19:202\u20138.","journal-title":"Curr Oncol"},{"key":"829_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/annonc\/mdr065","volume":"23","author":"T Buchler","year":"2012","unstructured":"Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma\u2014data from the Czech registry. Ann Oncol. 2012;23:395\u2013401.","journal-title":"Ann Oncol"},{"key":"829_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"829_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.18632\/oncotarget.182","volume":"1","author":"HM Schuller","year":"2010","unstructured":"Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget. 2010;1:466\u20139.","journal-title":"Oncotarget"},{"key":"829_CR15","doi-asserted-by":"publisher","first-page":"14094","DOI":"10.1074\/jbc.M611370200","volume":"282","author":"KS Sastry","year":"2007","unstructured":"Sastry KS, Karpova Y, Prokopovich S, Smith AJ, Essau B, Gersappe A, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem. 2007;282:14094\u2013100.","journal-title":"J Biol Chem"},{"key":"829_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.lfs.2011.04.007","volume":"88","author":"HP Wong","year":"2011","unstructured":"Wong HP, Ho JW, Koo MW, Yu L, Wu WK, Lam EK, et al. Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci. 2011;88:1108\u201312.","journal-title":"Life Sci"},{"key":"829_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/A:1024491219366","volume":"80","author":"TL Drell","year":"2003","unstructured":"Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003;80:63\u201370.","journal-title":"Breast Cancer Res Treat"},{"key":"829_CR18","doi-asserted-by":"publisher","first-page":"10357","DOI":"10.1158\/0008-5472.CAN-06-2496","volume":"66","author":"EV Yang","year":"2006","unstructured":"Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, andMMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006;66:10357\u201364.","journal-title":"Cancer Res"},{"key":"829_CR19","doi-asserted-by":"publisher","first-page":"29919","DOI":"10.1074\/jbc.M611539200","volume":"282","author":"MB Nilsson","year":"2007","unstructured":"Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, et al. Stress hormonesregulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007;282:29919\u201326.","journal-title":"J Biol Chem"},{"key":"829_CR20","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1073\/pnas.0911515107","volume":"107","author":"SW Cole","year":"2010","unstructured":"Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, et al. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl AcadSci USA. 2010;107:5681\u20136.","journal-title":"Proc Natl AcadSci USA"},{"key":"829_CR21","doi-asserted-by":"publisher","first-page":"35462","DOI":"10.1074\/jbc.M110.109579","volume":"285","author":"MM Shahzad","year":"2010","unstructured":"Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, et al. Stress effects on FosB and interleukin-8 (IL8) -driven ovarian cancer growth and metastasis. J Biol Chem. 2010;285:35462\u201370.","journal-title":"J Biol Chem"},{"key":"829_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm1447","volume":"12","author":"PH Thaker","year":"2006","unstructured":"Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939\u201344.","journal-title":"Nat Med"},{"key":"829_CR23","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/0008-5472.CAN-08-4289","volume":"69","author":"D Chakroborty","year":"2009","unstructured":"Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res. 2009;69:3727\u201330.","journal-title":"Cancer Res"},{"key":"829_CR24","first-page":"2866","volume":"61","author":"K Masur","year":"2001","unstructured":"Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 2001;61:2866\u20139.","journal-title":"Cancer Res"},{"key":"829_CR25","first-page":"825","volume":"22","author":"K Guo","year":"2009","unstructured":"Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep. 2009;22:825\u201330.","journal-title":"Oncol Rep"},{"key":"829_CR26","doi-asserted-by":"publisher","first-page":"e60021","DOI":"10.1371\/journal.pone.0060021","volume":"8","author":"JM Stiles","year":"2013","unstructured":"Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS ONE. 2013;8:e60021.","journal-title":"PLoS ONE"},{"key":"829_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","volume":"65","author":"HH Grytli","year":"2014","unstructured":"Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta- blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65:635\u201341.","journal-title":"Eur Urol"},{"key":"829_CR28","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","volume":"29","author":"TI Barron","year":"2011","unstructured":"Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29:2635\u201344.","journal-title":"J Clin Oncol"},{"key":"829_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-013-2654-3","volume":"140","author":"E Botteri","year":"2013","unstructured":"Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, et al. Therapeutic effect of \u03b2-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140:567\u201375.","journal-title":"Breast Cancer Res Treat"},{"key":"829_CR30","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1055-9965.EPI-11-0249","volume":"20","author":"S Lemeshow","year":"2011","unstructured":"Lemeshow S, Sorensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, et al. \u03b2-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomark Prev. 2011;20:2273\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"829_CR31","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/COC.0000000000000359","volume":"41","author":"MS Beg","year":"2018","unstructured":"Beg MS, Gupta A, Sher D, Ali S, Khan S, Gao A, et al. Impact of concurrent medication use on pancreatic cancer survival-SEER-medicare analysis. Am J Clin Oncol. 2018;41:766\u201371.","journal-title":"Am J Clin Oncol"},{"key":"829_CR32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/MD.0000000000000719","volume":"94","author":"R Giampieri","year":"2015","unstructured":"Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, Ridolfi F, et al. Prognostic value for incidental antihypertensive therapy with beta-blockers in metastatic colorectal cancer. Medicine. 2015;94:719.","journal-title":"Medicine"},{"key":"829_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ygyno.2012.07.102","volume":"127","author":"ES Diaz","year":"2012","unstructured":"Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol. 2012;127:375\u20138.","journal-title":"Gynecol Oncol"},{"key":"829_CR34","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mds616","volume":"24","author":"HM Wang","year":"2013","unstructured":"Wang HM, Liao ZX, Komaki R, Welsh JW, Reilly MS, Chang JY, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013;24:1312\u20139.","journal-title":"Ann Oncol"},{"key":"829_CR35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","volume":"37","author":"S Holmes","year":"2013","unstructured":"Holmes S, Griffith EJ, Musto G, Minuk GY. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol. 2013;37:881\u20135.","journal-title":"Cancer Epidemiol"},{"key":"829_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2016.11.012","volume":"144","author":"F Heitz","year":"2017","unstructured":"Heitz F, Hengsbach A, Harter P, Traut A, Ataseven B, Schneider S, et al. Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2017;144:181\u20136.","journal-title":"Gynecol Oncol"},{"key":"829_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-13-85","volume":"13","author":"SA Johannesdottir","year":"2013","unstructured":"Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, et al. Use of \u00df-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer. 2013;13:85.","journal-title":"BMC Cancer"},{"key":"829_CR38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","volume":"140","author":"CH Choi","year":"2014","unstructured":"Choi CH, Song TJ, Kim TH, Choi JK, Park JY, Yoon A, et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014;140:1179\u201388.","journal-title":"J Cancer Res Clin Oncol"},{"key":"829_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","volume":"25","author":"S Zhong","year":"2016","unstructured":"Zhong S, Yu D, Zhang X, Chen X, Yang S, Tang J, et al. \u03b2-blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Eur J Cancer Prev. 2016;25:440\u20138.","journal-title":"Eur J Cancer Prev"},{"key":"829_CR40","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.2147\/OTT.S167422","volume":"11","author":"Z Na","year":"2018","unstructured":"Na Z, Qiao X, Hao X, Fan L, Xiao Y, Shao Y, et al. The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients. Onco Targets Ther. 2018;11:4913\u201344.","journal-title":"Onco Targets Ther"},{"key":"829_CR41","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00432-019-02914-2","volume":"145","author":"E Neumann","year":"2019","unstructured":"Neumann E, Klaiber P, Freitag K, Schwab M, Schaeffeler E, Hennenlotter J, et al. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. J Cancer Res Clin Oncol. 2019;145:1835\u201343.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"36","key":"829_CR42","first-page":"e1","volume":"35","author":"WP Parker","year":"2017","unstructured":"Parker WP, Lohse CM, Zaid HB, Cheville JC, Boorjian SA, Leibovich BC, et al. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. Urol Oncol. 2017;35(36):e1-36.e6.","journal-title":"Urol Oncol"},{"key":"829_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11373-005-3008-x","volume":"12","author":"KG Shyu","year":"2005","unstructured":"Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1a and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12:409\u201320.","journal-title":"J Biomed Sci"},{"key":"829_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00431-010-1324-2","volume":"170","author":"C Schiestl","year":"2011","unstructured":"Schiestl C, Neuhaus K, Zoller S, Subotic U, Forster-Kuebler I, Michels R, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011;170:493\u2013501.","journal-title":"Eur J Pediatr"},{"key":"829_CR45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2133.2009.09597.x","volume":"162","author":"F Manunza","year":"2010","unstructured":"Manunza F, Syed S, Laguna B, Linward J, Kennedy H, Gholam K, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466\u20138.","journal-title":"Br J Dermatol"},{"key":"829_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1756-9966-33-21","volume":"33","author":"GH Deng","year":"2014","unstructured":"Deng GH, Liu J, Zhang J, Wang Y, Peng XC, Wei YQ, et al. Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model. J Exp Clin Cancer Res. 2014;33:21.","journal-title":"J Exp Clin Cancer Res"},{"key":"829_CR47","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.2217\/fon-2020-0548","volume":"16","author":"M Boegemann","year":"2020","unstructured":"Boegemann M, Schlack K, Rink M, Bernhardt S, Moran M, Hubbe M, et al. Effect of comorbidities\/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. Future Oncol. 2020;16:2939\u201348.","journal-title":"Future Oncol"},{"key":"829_CR48","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clgc.2017.05.019","volume":"15","author":"AA Lalani","year":"2017","unstructured":"Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK. Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2017;15:724\u201332.","journal-title":"Clin Genitourin Cancer"},{"key":"829_CR49","first-page":"10","volume":"9","author":"KK Chan","year":"2003","unstructured":"Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10\u20139.","journal-title":"Clin Cancer Res"},{"key":"829_CR50","first-page":"10","volume":"9","author":"K Keyomarsi","year":"2003","unstructured":"Keyomarsi K, Sandoval L, Band V. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 2003;9:10\u20139.","journal-title":"Cancer Res"},{"key":"829_CR51","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/sj.leu.2402476","volume":"16","author":"WW Wong","year":"2002","unstructured":"Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508\u201319.","journal-title":"Leukemia"},{"key":"829_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2015.10.008","volume":"52","author":"RR McKay","year":"2016","unstructured":"McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, et al. Statins and survival outcomes in patients with metastatic renal cell carcinoma. Eur J Cancer. 2016;52:155\u201362.","journal-title":"Eur J Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-021-00829-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T11:55:41Z","timestamp":1633002941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-021-00829-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00829-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"9 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by The Institutional Research Fund of University Hospital Plzen (FN 00669806), by the Charles University Research Fund (Progres Q39), by the European Regional Development Fund-Project \u201cApplication of Modern Technologies in Medicine and Industry\u201d (No. CZ.02.1.01\/0.0\/0.0\/17_048\/0007280), by a grant from the Ministry of Health of the Czech Republic (AZV NV19-08-00250), and by the European Union's Horizon 2020 research and innovation program (Grant Agreement No. 856620).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"OF has received honoraria from Roche, Janssen, GSK, and Pfizer for consultations and lectures unrelated to this project. MH has received honoraria for lecture, tutoring, clinical trials, or travel grants from Astellas, Janssen-Cilag, and Roche. J. Finek has received honoraria from Astra Zeneca, Roche, and Novartis for consultations and lectures unrelated to this project. TB has received lecture honoraria from Novartis, Ipsen, Pfizer, Bayer, Amgen, Servier, Bristol Myers Squibb, Astellas, Janssen, and Roche and research support from Roche, Servier, and Novartis, all unrelated to the presented work. PO, AR, OS, JS, BB, IT and J. Filipovsky have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the study protocol, the ethical principles stated in the Declaration of Helsinki as well as those indicated in the International Conference on Harmonization Guidance on Good Clinical Practice (1995), and all applicable regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed written informed consent before study entry. Adequate information was given to eligible patients by the principal investigator or co-investigators at each participating center and in accordance with local regulations. The declaration of informed consent was personally signed and dated by the subject and by the investigator\/person designated by the investigator to conduct the informed consent discussion.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding the publication of their data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"OF designed the study. OF and TB wrote the manuscript with support from PO, AR, MH, OS, JS, BB, IT, J. Finek and J. Filipovsky. PO performed statistical analyses.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}